Keiichi Ishida, Hiroki Kohno, Kaoru Matsuura, Toshihiko Sugiura, Takayuki J Sanada, Akira Naito, Ayako Shigeta, Rika Suda, Ayumi Sekine, Masahisa Masuda, Seiichiro Sakao, Nobuhiro Tanabe, Koichiro Tatsumi, Goro Matsumiya
Residual pulmonary hypertension (PH) negatively impacts long-term results following pulmonary endarterectomy (PEA) for chronic thromboembolic pulmonary hypertension (CTEPH). We sought to reveal whether modern PH therapy with PH-targeted medicine and balloon pulmonary angioplasty (BPA) improved long-term results of residual PH after PEA. Long-term findings of 80 patients who survived PEA between 2011 and 2019 were retrospectively investigated. One month after PEA, 30 patients developed residual PH defined as mean pulmonary artery pressure (mPAP) ≥25 mmHg, of whom 23 were treated by PH-targeted medicine and 9 by BPA...
April 2023: Pulmonary Circulation